SLC19A1 and central nervous system cancer: Kalan–Meier curves suggest that higher SLC19A1 promoter methylation level predicts a better prognosis in BLAD, BRCA, basal-like BRCA, glioma, SKCM, and SKCM metastasis (Figure 3D).